69 results match your criteria Journal of Immune Based Therapies and Vaccines[Journal]


Paratuberculosis control: a review with a focus on vaccination.

J Immune Based Ther Vaccines 2011 Oct 31;9. Epub 2011 Oct 31.

NEIKER-Tecnalia, Department of Animal Health, Berreaga 1, 48160 Derio, Bizkaia, Spain.

Mycobacterium avium subsp. paratuberculosis (MAP) infection causes in ruminants a regional chronic enteritis that is increasingly being recognized as a significant problem affecting animal health, farming and the food industry due to the high prevalence of the disease and to recent research data strengthening the link between the pathogen and human inflammatory bowel disease (IBD). Control of the infection through hygiene-management measures and test and culling of positive animals has to date not produced the expected results and thus a new focus on vaccination against this pathogen is necessary. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-8518-9-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3222599PMC
October 2011
16 Reads

Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an Epidermal Growth Factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patients.

J Immune Based Ther Vaccines 2011 Oct 24;9. Epub 2011 Oct 24.

Center of Molecular Immunology, PO Box: 16040, Havana 11600, Cuba.

The prognosis of patients with advanced non small cell lung (NSCLC) cancer remains dismal. Epidermal Growth Factor Receptor is over-expressed in many epithelial derived tumors and its role in the development and progression of NSCLC is widely documented. CimaVax-EGF is a therapeutic cancer vaccine composed by human recombinant Epidermal Growth Factor (EGF) conjugated to a carrier protein, P64K from Neisseria Meningitides. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-8518-9-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3215653PMC
October 2011
13 Reads
4 Citations

Immunization with genetically attenuated P52-deficient Plasmodium berghei sporozoites induces a long-lasting effector memory CD8+ T cell response in the liver.

J Immune Based Ther Vaccines 2011 Oct 17;9(1). Epub 2011 Oct 17.

Unidade de Malaria, Instituto de Medicina Molecular, Universidade de Lisboa, Av Professor Egas Moniz, Lisboa, 1649-028, Portugal.

Background: The induction of sterile immunity and long lasting protection against malaria has been effectively achieved by immunization with sporozoites attenuated by gamma-irradiation or through deletion of genes. For mice immunized with radiation attenuated sporozoites (RAS) it has been shown that intrahepatic effector memory CD8+ T cells are critical for protection. Recent studies have shown that immunization with genetically attenuated parasites (GAP) in mice is also conferred by liver effector memory CD8+ T cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-8518-9-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3206817PMC
October 2011
11 Reads

Formulation of a killed whole cell pneumococcus vaccine - effect of aluminum adjuvants on the antibody and IL-17 response.

J Immune Based Ther Vaccines 2011 Jul 29;9. Epub 2011 Jul 29.

Department of Comparative Pathobiology, Purdue University, 725 Harrison Street, West Lafayette, IN 47907, USA.

Background: Streptococcus pneumoniae causes widespread morbidity and mortality. Current vaccines contain free polysaccharides or protein-polysaccharide conjugates, and do not induce protection against serotypes that are not included in the vaccines. An affordable and broadly protective vaccine is very desirable. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-8518-9-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3161839PMC
July 2011
7 Reads

Immunotherapeutic role of Ag85B as an adjunct to antituberculous chemotherapy.

J Immune Based Ther Vaccines 2011 Jun 26;9. Epub 2011 Jun 26.

Department of Biochemistry, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India.

Background: Immunotherapy to enhance the efficiency of the immune response in tuberculosis patients and to eliminate the persisters could be an additional valuable strategy to complement anti-mycobacterial chemotherapy. This study was designed to assess the immunotherapeutic potential of Ag85B as an adjunct to chemotherapy and its effect against active and persister bacteria left after therapy in mouse model of tuberculosis.

Methods: 6-8 week old female Balb/c mice were infected with Mycobacterium tuberculosis and treated with chemotherapy or immunotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-8518-9-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3142482PMC
June 2011
5 Reads

Phase IIb randomized trial of adjunct immunotherapy in patients with first-diagnosed tuberculosis, relapsed and multi-drug-resistant (MDR) TB.

J Immune Based Ther Vaccines 2011 Jan 18;9. Epub 2011 Jan 18.

Department of Phtysiatry and Pulmonology, Kharkov National Medical University; Kharkov, Ukraine.

Placebo-controlled, randomized, phase 2b trial was conducted in 34 adults comprising 18 first-diagnosed (52.9%), 6 relapsed (17.6%), and 10 MDR-TB (29. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-8518-9-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3031205PMC
January 2011
22 Reads

Prior exposure to an attenuated Listeria vaccine does not reduce immunogenicity: pre-clinical assessment of the efficacy of a Listeria vaccine in the induction of immune responses against HIV.

J Immune Based Ther Vaccines 2011 Jan 18;9. Epub 2011 Jan 18.

Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA.

Background: We have evaluated an attenuated Listeria monocytogenes (Lm) candidate vaccine vector in nonhuman primates using a delivery regimen relying solely on oral vaccination. We sought to determine the impact of prior Lm vector exposure on the development of new immune responses against HIV antigens.

Findings: Two groups of rhesus macaques one Lm naive, the other having documented prior Lm vector exposures, were evaluated in response to oral inoculations of the same vector expressing recombinant HIV-1 Gag protein. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-8518-9-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3033796PMC
January 2011
7 Reads

Dendritic cell therapy for oncology roundtable conference.

Authors:
Sandra Tuyaerts

J Immune Based Ther Vaccines 2011 Jan 12;9(1). Epub 2011 Jan 12.

Laboratory of Experimental Gynaecology, Department of Woman & Child, Catholic University of Leuven (K,U, Leuven), Belgium.

2-3 September 2010, Brussels, BelgiumThe Dendritic Cell Therapy for Oncology Roundtable Conference was organized by Reliable Cancer Therapies and moderated by Prof. Dr. Steven De Vleeschouwer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-8518-9-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3027086PMC
January 2011
7 Reads

Generation and characterization of high affinity human monoclonal antibodies that neutralize staphylococcal enterotoxin B.

J Immune Based Ther Vaccines 2010 Dec 21;8. Epub 2010 Dec 21.

Morphotek Inc,, 210 Welsh Pool Road, Exton, PA, USA.

Background: Staphylococcal enterotoxins are considered potential biowarfare agents that can be spread through ingestion or inhalation. Staphylococcal enterotoxin B (SEB) is a widely studied superantigen that can directly stimulate T-cells to release a massive amount of proinflammatory cytokines by bridging the MHC II molecules on an antigen presenting cell (APC) and the Vβ chains of the T-cell receptor (TCR). This potentially can lead to toxic, debilitating and lethal effects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-8518-8-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3022601PMC
December 2010
12 Reads

Ex vivo development, expansion and in vivo analysis of a novel lineage of dendritic cells from hematopoietic stem cells.

J Immune Based Ther Vaccines 2010 Nov 24;8. Epub 2010 Nov 24.

Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, Florida, 32610 USA.

Dendritic cells (DCs) play a key role in innate and adaptive immunity but the access to sufficient amount of DCs for basic and translational research has been limited.We established a novel ex vivo system to develop and expand DCs from hematopoietic stem/progenitor cells (HPCs). Both human and mouse HPCs were expanded first in feeder culture supplemented with c-Kit ligand (KL, stem cell factor, steel factor or CD117 ligand), Flt3 ligand (fms-like tyrosine kinase 3, Flt3L, FL), thrombopoietin (TPO), IL-3, IL-6, and basic fibroblast growth factor (bFGF), and then in a second feeder culture ectopically expressing all above growth factors plus GM-CSF and IL-15. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-8518-8-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004889PMC
November 2010
18 Reads

HIV-1 sub-type C chimaeric VLPs boost cellular immune responses in mice.

J Immune Based Ther Vaccines 2010 Nov 19;8. Epub 2010 Nov 19.

Department of Molecular and Cell Biology, Faculty of Science, University of Cape Town, University Ave, Rondebosch 7701, South Africa.

Several approaches have been explored to eradicate HIV; however, a multigene vaccine appears to be the best option, given their proven potential to elicit broad, effective responses in animal models. The Pr55Gag protein is an excellent vaccine candidate in its own right, given that it can assemble into large, enveloped, virus-like particles (VLPs) which are highly immunogenic, and can moreover be used as a scaffold for the presentation of other large non-structural HIV antigens. In this study, we evaluated the potential of two novel chimaeric HIV-1 Pr55Gag-based VLP constructs - C-terminal fusions with reverse transcriptase and a Tat::Nef fusion protein, designated GagRT and GagTN respectively - to enhance a cellular response in mice when used as boost components in two types of heterologous prime-boost vaccine strategies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-8518-8-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2996383PMC
November 2010
12 Reads

Antiviral activity of Engystol® and Gripp-Heel®: an in-vitro assessment.

J Immune Based Ther Vaccines 2010 Nov 16;8. Epub 2010 Nov 16.

Biologische Heilmittel Heel GmbH, Baden-Baden, Germany.

Background: Infections with respiratory viruses can activate the innate immune response - an important host defence mechanism in the early stage of viral infection. Interferon (IFN) release, triggered by virus infection, is an important factor in establishing an antiviral state, where IFN activation occurs prior to the onset of the adaptive immune response.The two ultra-low-dose combination medications, Engystol® and Gripp-Heel®, have documented efficacy for the treatment of the respiratory infections. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-8518-8-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2998502PMC
November 2010
12 Reads

Probing local innate immune responses after mucosal immunisation.

J Immune Based Ther Vaccines 2010 Sep 13;8. Epub 2010 Sep 13.

Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridgeshire, CB10 1SA, UK.

Background: Intranasal immunisation is potentially a very effective route for inducing both mucosal and systemic immunity to an infectious agent.

Methods: Balb/c mice were intranasally immunised with the mucosal adjuvant heat labile toxin and the Mycobacterium tuberculosis fusion protein Ag85B-ESAT6 and early changes in innate immune responses within local mucosal tissues were examined using flow cytometry and confocal microscopy. Antigen-specific humoral and cellular immune responses were also evaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-8518-8-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2945349PMC
September 2010
6 Reads

PCEP enhances IgA mucosal immune responses in mice following different immunization routes with influenza virus antigens.

J Immune Based Ther Vaccines 2010 Aug 24;8. Epub 2010 Aug 24.

Vaccine & Infectious Disease Organization/International Vaccine Center, University of Saskatchewan, 120 Veterinary Road, Saskatoon, Saskatchewan, S7N 5E3, Canada.

Background: We previously demonstrated that polyphosphazenes, particularly PCEP, enhance immune responses in mice immunized subcutaneously and intranasally. The objective of the present study was to investigate the efficacy of polyphosphazenes as adjuvants when delivered through different routes of vaccine administration.

Methods: BALB/c mice were immunized through intranasal, subcutaneous, oral and intrarectal delivery with vaccine formulations containing either influenza X:31 antigen alone or formulated in PCEP. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-8518-8-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2936874PMC
August 2010
6 Reads

Assessment of immune response to repeat stimulation with BCG vaccine using in vitro PBMC model.

J Immune Based Ther Vaccines 2010 May 28;8. Epub 2010 May 28.

Biochemistry Research Laboratory, Central India Institute of Medical Sciences, 88/2 Bajaj Nagar, Nagpur-440010, India.

Background: Tuberculosis (TB) is one of the most prevalent cause of death due to a single pathogen. Bacillus Calmette Guérin (BCG) is the only vaccine available for clinical use that protects against miliary TB; however, this vaccine has shown variable levels of efficacy against pulmonary TB. In India, a single dose of BCG vaccine is given and there are few countries where repeated doses of BCG are given. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-8518-8-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2890520PMC
May 2010
6 Reads

CD40mAb adjuvant induces a rapid antibody response that may be beneficial in post-exposure prophylaxis.

J Immune Based Ther Vaccines 2010 Feb 4;8. Epub 2010 Feb 4.

Department of Infection and Immunity, University of Sheffield Medical School, Beech Hill Rd, Sheffield S10 2RX, UK.

Active vaccination can be effective as a post-exposure prophylaxis, but the rapidity of the immune response induced, relative to the incubation time of the pathogen, is critical. We show here that CD40mAb conjugated to antigen induces a more rapid specific antibody response than currently used immunological adjuvants, alum and monophosphoryl lipid A. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-8518-8-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2824643PMC
February 2010
7 Reads

CpG oligodeoxyribonucleotides protect mice from Burkholderia pseudomallei but not Francisella tularensis Schu S4 aerosols.

J Immune Based Ther Vaccines 2010 Feb 5;8(1). Epub 2010 Feb 5.

Bacteriology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA.

Studies have shown that CpG oligodeoxyribonucleotides (ODN) protect mice from various bacterial pathogens, including Burkholderia pseudomallei and Francisella tularensis live vaccine strain (LVS), when administered before parenteral challenge. Given the potential to develop CpG ODN as a pre-treatment for multiple bacterial biological warfare agents, we examined survival, histopathology, and cytokine data from CpG ODN-treated C57BL/6 mice to determine whether previously-reported protection extended to aerosolized B. pseudomallei 1026b and highly virulent F. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-8518-8-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2830940PMC
February 2010
7 Reads

HIV-1 neutralization by monoclonal antibody against conserved region 2 and patterns of epitope exposure on the surface of native viruses.

J Immune Based Ther Vaccines 2009 Oct 12;7. Epub 2009 Oct 12.

Department of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Background: Conserved neutralizing epitopes are considered to be a key role for eliciting broadly neutralizing antibody (NAb). Previously, two conserved neutralizing epitopes of HIV-1 CRF01_AE envelope were identified at amino acid 93-112 of the C1 (C1E) and at 218-239 of the C2 (C2E) regions. To access the potency of antibody directed against conserved epitopes, a monoclonal antibody (MAb) specific to the C2E region was developed and characterized. Read More

View Article

Download full-text PDF

Source
http://jibtherapies.biomedcentral.com/articles/10.1186/1476-
Publisher Site
http://dx.doi.org/10.1186/1476-8518-7-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2770445PMC
October 2009
7 Reads

DNA vaccine containing the mycobacterial hsp65 gene prevented insulitis in MLD-STZ diabetes.

J Immune Based Ther Vaccines 2009 Sep 15;7. Epub 2009 Sep 15.

University of São Paulo, Ribeirão Preto Medical School, Department of Biochemistry and Immunology, Ribeirão Preto, São Paulo, Brazil.

Background: Our group previously demonstrated that a DNA plasmid encoding the mycobacterial 65-kDa heat shock protein (DNA-HSP65) displayed prophylactic and therapeutic effect in a mice model for tuberculosis. This protection was attributed to induction of a strong cellular immunity against HSP65. As specific immunity to HSP60 family has been detected in arthritis, multiple sclerosis and diabetes, the vaccination procedure with DNA-HSP65 could induce a cross-reactive immune response that could trigger or worsen these autoimmune diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-8518-7-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2754477PMC
September 2009
7 Reads

Prospects for control of emerging infectious diseases with plasmid DNA vaccines.

Authors:
Ronald B Moss

J Immune Based Ther Vaccines 2009 Sep 7;7. Epub 2009 Sep 7.

Vical Inc, San Diego, CA, USA.

Experiments almost 20 years ago demonstrated that injections of a sequence of DNA encoding part of a pathogen could stimulate immunity. It was soon realized that "DNA vaccination" had numerous potential advantages over conventional vaccine approaches including inherent safety and a more rapid production time. These and other attributes make DNA vaccines ideal for development against emerging pathogens. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-8518-7-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2746192PMC
September 2009
6 Reads

The first influenza pandemic in the new millennium: lessons learned hitherto for current control efforts and overall pandemic preparedness.

J Immune Based Ther Vaccines 2009 Aug 7;7. Epub 2009 Aug 7.

Infectious Diseases and Clinical Immunology Unit, Department of Experimental Medicine, School of Medicine, Universidad Nacional Autónoma de México, Dr, Balmis 148, Col, Doctores, México.

Influenza viruses pose a permanent threat to human populations due to their ability to constantly adapt to impact immunologically susceptible individuals in the forms of epidemic and pandemics through antigenic drifts and antigenic shifts, respectively. Pandemic influenza preparedness is a critical step in responding to future influenza outbreaks. In this regard, responding to the current pandemic and preparing for future ones requires critical planning for the early phases where there is no availability of pandemic vaccine with rapid deployment of medical supplies for personal protection, antivirals, antibiotics and social distancing measures. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-8518-7-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2731762PMC
August 2009
9 Reads

Evaluation of recombinant invasive, non-pathogenic Eschericia coli as a vaccine vector against the intracellular pathogen, Brucella.

J Immune Based Ther Vaccines 2009 Jan 6;7. Epub 2009 Jan 6.

Department of Pathobiological Sciences, University of Wisconsin-Madison, 1656 Linden Drive, Madison, WI 53706, USA.

Background: There is no safe, effective human vaccine against brucellosis. Live attenuated Brucella strains are widely used to vaccinate animals. However these live Brucella vaccines can cause disease and are unsafe for humans. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-8518-7-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2633335PMC
January 2009
6 Reads

Vaccine based on a ubiquitous cysteinyl protease and streptococcal pyrogenic exotoxin A protects against Streptococcus pyogenes sepsis and toxic shock.

Authors:
Robert G Ulrich

J Immune Based Ther Vaccines 2008 Oct 31;6. Epub 2008 Oct 31.

Laboratory of Molecular Immunology, Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Frederick, Maryland 21702, USA.

Background: The gram-positive bacterium Streptococcus pyogenes is a common pathogen of humans that causes invasive infections, toxic-shock syndrome, rheumatic fever, necrotizing fasciitis and other diseases. Detection of antibiotic resistance in clinical isolates has renewed interest in development of new vaccine approaches for control S. pyogenes sepsis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-8518-6-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585077PMC
October 2008
12 Reads

Effects of recombinant human growth hormone on HIV-1-specific T-cell responses, thymic output and proviral DNA in patients on HAART: 48-week follow-up.

J Immune Based Ther Vaccines 2008 Oct 31;6. Epub 2008 Oct 31.

Department of Immunology, Imperial College London, Chelsea and Westminster Hospital, 369 Fulham Road, London, SW10 9NH, UK .

Background: Efficacious immune-based therapy in treated chronic HIV-1 infection requires the induction of virus-specific CD4+ T cells and subsequent maturation and maintenance of specific memory CD8+ T cells. Concomitant daily administration of recombinant human growth hormone (rhGH) with highly active antiretroviral therapy (HAART) was used in chronically infected patients with lipodystrophy in an attempt to reconstitute these virus-specific T-cell responses.

Methods: Individuals with chronic HIV-1 infection on HAART were enrolled on a randomized, double-blinded, placebo-controlled study to receive rhGH therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-8518-6-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2613878PMC
October 2008
13 Reads

CXCL10 blockade protects mice from cyclophosphamide-induced cystitis.

J Immune Based Ther Vaccines 2008 Oct 28;6. Epub 2008 Oct 28.

Department of Microbiology and Immunology, University of Louisville, Louisville, KY, USA.

Background: Alterations in serum CXCR3 ligand levels were examined in interstitial cystitis (IC) patients; similar expression patterns in serum as well as CXCR3, CXCR3 ligands, and cytokines expressed by peripheral and local leukocyte subpopulations were characterized during cyclophosphamide (CYP)-induced acute cystitis in mice.

Results: Serum levels of monokine-induced by interferon-gamma (IFN-gamma) (MIG/CXCL9), IFN-gamma-inducible protein-10 (IP-10/CXCL10), and IFN-gamma-inducible T cell alpha chemoattractant (I-TAC/CXCL11) were elevated in patients with IC. These clinical features closely correlated with CYP-induced cystitis in mice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-8518-6-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2583981PMC
October 2008
17 Reads

An alternative approach to combination vaccines: intradermal administration of isolated components for control of anthrax, botulism, plague and staphylococcal toxic shock.

J Immune Based Ther Vaccines 2008 Sep 3;6. Epub 2008 Sep 3.

Department of Immunology, Army Medical Research Institute of Infectious Diseases, Frederick, MD, USA.

Background: Combination vaccines reduce the total number of injections required for each component administered separately and generally provide the same level of disease protection. Yet, physical, chemical, and biological interactions between vaccine components are often detrimental to vaccine safety or efficacy.

Methods: As a possible alternative to combination vaccines, we used specially designed microneedles to inject rhesus macaques with four separate recombinant protein vaccines for anthrax, botulism, plague and staphylococcal toxic shock next to each other just below the surface of the skin, thus avoiding potentially incompatible vaccine mixtures. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-8518-6-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2543000PMC
September 2008
16 Reads

CpG increases vaccine antigen-specific cell-mediated immunity when administered with hepatitis B vaccine in HIV infection.

J Immune Based Ther Vaccines 2008 Aug 12;6. Epub 2008 Aug 12.

Ottawa Health Research Institute, 501 Smyth Rd., Ottawa, ON, K1H 8L6, Canada.

Background: Lack of adequate adjuvancy is a possible explanation for lack of vaccine immunogenecity. Immunostimulatory CpGs are potent vaccine adjuvants and may be an important component of the development vaccines, particularly those for which a cellular immune response is required for protection. We have previously demonstrated that CpG ODN co-administration with hepatitis B vaccine results in earlier, stronger and more sustained antibody responses to hepatitis B surface antigen in HIV infected individuals, and wished to determine if, in this population, helper T-cell responses were also enhanced. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-8518-6-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2526993PMC
August 2008
9 Reads

Immunostimulatory effects of three classes of CpG oligodeoxynucleotides on PBMC from HCV chronic carriers.

J Immune Based Ther Vaccines 2008 Jun 9;6. Epub 2008 Jun 9.

Coley Pharmaceutical Canada, Ottawa, Canada.

Background: Chronic hepatitis C virus (HCV) infection results from weak or absent T cell responses. Pegylated-interferon-alpha (IFN-alpha) and ribavirin, the standard of care for chronic HCV, have numerous immune effects but are not potent T cell activators. A potent immune activator such as TLR9 agonist CpG oligodeoxynucleotide (CpG) may complement current treatment approaches. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-8518-6-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2430961PMC
June 2008
13 Reads

Use of ultraviolet-light irradiated multiple myeloma cells as immunogens to generate tumor-specific cytolytic T lymphocytes.

J Immune Based Ther Vaccines 2008 Apr 28;6. Epub 2008 Apr 28.

Cancer Immunology Laboratory, Department of Clinical Research, Singapore General Hospital, Outram Road, 169608 Singapore.

Background: As the eradication of tumor cells in vivo is most efficiently performed by cytolytic T lymphocytes (CTL), various methods for priming tumor-reactive lymphocytes have been developed. In this study, a method of priming CTLs with ultraviolet (UV)-irradiated tumor cells, which results in termination of tumor cell proliferation, apoptosis, as well as upregulation of heat shock proteins (HSP) expression is described.

Methods: Peripheral blood mononuclear cells (PBMC) were primed weekly with UV-irradiated or mitomycin-treated RPMI 8226 multiple myeloma cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-8518-6-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2383894PMC
April 2008
8 Reads

A new approach for the large-scale generation of mature dendritic cells from adherent PBMC using roller bottle technology.

J Immune Based Ther Vaccines 2008 Mar 6;6. Epub 2008 Mar 6.

Department of Melanoma Medical Oncology, University of Texas, M,D, Anderson Cancer Center, Houston, TX, 77030, USA.

Background: Human monocyte-derived DC (mDC) loaded with peptides, protein, tumor cell lysates, or tumor cell RNA, are being tested as vaccines against multiple human malignancies and viral infection with great promise. One of the factors that has limited more widespread use of these vaccines is the need to generate mDC in large scale. Current methods for the large-scale cultivation of mDC in static culture vessels are labor- and time- intensive, and also require many culture vessels. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-8518-6-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2292722PMC
March 2008
9 Reads

An HIV/AIDS Prophylactic vaccine is possible.

J Immune Based Ther Vaccines 2007 Dec 19;5:12. Epub 2007 Dec 19.

Department of Microbiology, Immunology and Parasitology, Louisiana State University Health Sciences Center, New Orleans, LA, USA.

One needs to think outside of the box, as one of us (Ronald B Luftig) learned from many years as a mathematician, and a biophysicist.In this short Review, the need to focus on producing high levels of neutralizing antibodies (NAbs) to incoming and conformationally altered virus after it has bound to CD4+ cells is essential.Increasing the number of gp120 molecules on the surface of L-2 particles, could allow for an enhanced number of NAbs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-8518-5-12DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2234407PMC
December 2007
9 Reads

Rapid generation of an anthrax immunotherapeutic from goats using a novel non-toxic muramyl dipeptide adjuvant.

J Immune Based Ther Vaccines 2007 Oct 22;5:11. Epub 2007 Oct 22.

Wadsworth Center, New York State Department of Health, Biodefense Laboratory, Albany, NY, USA.

Background: There is a clear need for vaccines and therapeutics for potential biological weapons of mass destruction and emerging diseases. Anthrax, caused by the bacterium Bacillus anthracis, has been used as both a biological warfare agent and bioterrorist weapon previously. Although antibiotic therapy is effective in the early stages of anthrax infection, it does not have any effect once exposed individuals become symptomatic due to B. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-8518-5-11DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2104530PMC
October 2007
10 Reads
3 Citations

Specific antibody response of mice after immunization with COS-7 cell derived avian influenza virus (H5N1) recombinant proteins.

J Immune Based Ther Vaccines 2007 Oct 3;5:10. Epub 2007 Oct 3.

Department of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

To develop avian influenza H5N1 recombinant protein, the hemagglutinin (HA), neuraminidase (NA), matrix (M), and non-structural (NS1) of avian influenza H5N1 isolates from Thailand were engineered to be expressed in prokaryotic (E. coli) and mammalian cell (COS-7) system. The plasmid pBAD-His and pSec-His were used as vectors for these inserted genes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-8518-5-10DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2217519PMC
October 2007
9 Reads

CTLA-4 blockade during dendritic cell based booster vaccination influences dendritic cell survival and CTL expansion.

J Immune Based Ther Vaccines 2007 Jul 29;5. Epub 2007 Jul 29.

Department of International Health, Immunology and Microbiology, The Panum Institute, University of Copenhagen, Denmark.

Dendritic cells (DCs) are potent antigen-presenting cells and critical for the priming of CD8+ T cells. Therefore the use of these cells as adjuvant cells has been tested in a large number of experimental and clinical vaccination studies, in particular cancer vaccine studies. A number of protocols are emerging that combine vaccination with CTL expanding strategies, such as e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-8518-5-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1950502PMC
July 2007
7 Reads

Age-related waning of in vitro Interferon-gamma levels against r32kDaBCG in BCG vaccinated children.

J Immune Based Ther Vaccines 2007 Jun 7;5. Epub 2007 Jun 7.

LEPRA Society - Blue Peter Research Center, Hyderabad, AP, India.

Background: Mycobacterium bovis BCG vaccine has displayed inconsistent efficacy in different trials conducted in various geographical regions. Nevertheless, it significantly reduces the risk of severe childhood tuberculosis and continues to be used to prevent tuberculosis in many countries. Many studies revealed that efficacy of vaccine wanes with age. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-8518-5-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1899498PMC
June 2007
7 Reads

Phenotype and in vitro function of mature MDDC generated from cryopreserved PBMC of cancer patients are equivalent to those from healthy donors.

J Immune Based Ther Vaccines 2007 May 3;5. Epub 2007 May 3.

BD Biosciences Immunocytometry Systems, 2350 Qume Dr, San Jose, CA 95131, USA.

Background: Monocyte-derived-dendritic-cells (MDDC) are the major DC type used in vaccine-based clinical studies for a variety of cancers. In order to assess whether in vitro differentiated MDDC from cryopreserved PBMC of cancer patients are functionally distinct from those of healthy donors, we compared these cells for their expression of co-stimulatory and functional markers. In addition, the effect of cryopreservation of PBMC precursors on the quality of MDDC was also evaluated using samples from healthy donors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-8518-5-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1868730PMC
May 2007
14 Reads

A phase I, randomized study of combined IL-2 and therapeutic immunisation with antiretroviral therapy.

J Immune Based Ther Vaccines 2007 Apr 11;5. Epub 2007 Apr 11.

Department of Immunology, Imperial College London, Chelsea and Westminster Hospital, 369 Fulham Road, London, SW10 9NH, UK.

Background: Fully functional HIV-1-specific CD8 and CD4 effector T-cell responses are vital to the containment of viral activity and disease progression. These responses are lacking in HIV-1-infected patients with progressive disease. We attempted to augment fully functional HIV-1-specific CD8 and CD4 effector T-cell responses in patients with advanced chronic HIV-1 infection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-8518-5-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1864986PMC
April 2007
5 Reads

IMP321 (sLAG-3), an immunopotentiator for T cell responses against a HBsAg antigen in healthy adults: a single blind randomised controlled phase I study.

J Immune Based Ther Vaccines 2007 Mar 29;5. Epub 2007 Mar 29.

Immutep S.A., Parc Club Orsay, 2 rue Jean Rostand 91893, Orsay, France.

Background: LAG-3 (CD223) is a natural high affinity ligand for MHC class II. The soluble form (sLAG-3) induces maturation of monocyte-derived dendritic cells in vitro and is used as a potent Th1-like immune enhancer with many antigens in animal models. To extend this observation to human, a proof of concept study was conducted with a clinical-grade sLAG-3, termed IMP321, coinjected with alum-non-absorbed recombinant hepatitis B surface antigen. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-8518-5-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1852106PMC
March 2007
5 Reads

Evaluation of a recombinant human gelatin as a substitute for a hydrolyzed porcine gelatin in a refrigerator-stable Oka/Merck live varicella vaccine.

J Immune Based Ther Vaccines 2007 Feb 23;5. Epub 2007 Feb 23.

Vaccine Clinical Research, Merck Research Laboratories, P,O, Box 1000, UG3CD28, North Wales, PA 19454, USA.

Background: The labile nature of live, attenuated varicella-zoster virus (Oka/Merck) requires robust stabilization during virus bulk preparation and vaccine manufacturing in order to preserve potency through storage and administration. One stabilizing ingredient used in a varicella-zoster virus (VZV) vaccine is hydrolyzed porcine gelatin which represents the major protein/peptide-based excipient in the vaccine formulation.

Methods: In this comparative study, a recombinant human gelatin fragment (8. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-8518-5-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1808055PMC
February 2007
7 Reads

Improved generation of anti-tumor immunity by antigen dose limitation.

J Immune Based Ther Vaccines 2007 Feb 9;5. Epub 2007 Feb 9.

Department of Dermatology, Yale University, 333 Cedar Street, New Haven, CT USA.

Background: The malignant cells of cutaneous T cell lymphoma (CTCL) display immunogenic peptides derived from the clonal T cell receptor (TCR) providing an attractive model for refinement of anti-tumor immunization methodology. To produce a clinically meaningful anti-tumor response, induction of cytotoxic anti-CTCL cells must be maximized while suppressive T regulatory cells (Treg) should be minimized. We have demonstrated that engulfment of apoptotic CTCL cells by dendritic cells (DC) can lead to either CD8 anti-CTCL responses or immunosuppressive Treg induction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-8518-5-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1800896PMC
February 2007
9 Reads

The effect of CpG-ODN on antigen presenting cells of the foal.

J Immune Based Ther Vaccines 2007 Jan 25;5. Epub 2007 Jan 25.

Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, USA.

Background: Cytosine-phosphate-guanosine oligodeoxynucleotide (CpG-ODN) has been used successfully to induce immune responses against viral and intracellular organisms in mammals. The main objective of this study was to test the effect of CpG-ODN on antigen presenting cells of young foals.

Methods: Peripheral blood monocytes of foals (n = 7) were isolated in the first day of life and monthly thereafter up to 3 months of life. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-8518-5-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1797044PMC
January 2007
6 Reads

Longitudinal changes in HIV-specific IFN-gamma secretion in subjects who received Remune vaccination prior to treatment interruption.

J Immune Based Ther Vaccines 2006 Nov 28;4. Epub 2006 Nov 28.

McGill University Health Centre, Montreal, Quebec, Canada.

Background: Despite the benefits of highly active antiretroviral therapy (HAART) for suppressing viral replication in HIV infection, virus persists and rebounds during treatment interruption (TI). This study explored whether HAART intensification with Remune vaccination before TI can boost HIV-1-specific immunity, leading to improved control of viremia off HAART.

Methods: Ten chronically HIV-infected adults were enrolled in this proof of concept study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-8518-4-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1687183PMC
November 2006
13 Reads

Phytol-based novel adjuvants in vaccine formulation: 1. assessment of safety and efficacy during stimulation of humoral and cell-mediated immune responses.

J Immune Based Ther Vaccines 2006 Oct 30;4. Epub 2006 Oct 30.

Department of Life Sciences, Indiana State University, Terre Haute, IN 47809, USA.

Background: Vaccine efficacy depends significantly on the use of appropriate adjuvant(s) in the formulation. Phytol, a dietary diterpene alcohol, is similar in structure to naturally occurring isoprenoid adjuvants; but little is known of its adjuvanticity. In this report, we describe the relative safety and efficacy of phytol and its hydrogenated derivative PHIS-01 compared to commercial adjuvants. Read More

View Article

Download full-text PDF

Source
http://jibtherapies.biomedcentral.com/articles/10.1186/1476-
Publisher Site
http://dx.doi.org/10.1186/1476-8518-4-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1635037PMC
October 2006
7 Reads

Phytol-based novel adjuvants in vaccine formulation: 2. Assessment of efficacy in the induction of protective immune responses to lethal bacterial infections in mice.

J Immune Based Ther Vaccines 2006 Oct 23;4. Epub 2006 Oct 23.

Department of Life Sciences, Indiana State University, Terre Haute, IN 47809, USA.

Background: Adjuvants are known to significantly enhance vaccine efficacy. However, commercial adjuvants often have limited use because of toxicity in humans. The objective of this study was to determine the comparative effectiveness of a diterpene alcohol, phytol and its hydrogenated derivative PHIS-01, relative to incomplete Freund's adjuvant (IFA), a commonly used adjuvant in augmenting protective immunity in mice against E. Read More

View Article

Download full-text PDF

Source
http://jibtherapies.biomedcentral.com/articles/10.1186/1476-
Publisher Site
http://dx.doi.org/10.1186/1476-8518-4-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1633728PMC
October 2006
8 Reads

Modulation of humoral immune response to oral BCG vaccination by Mycobacterium bovis BCG Moreau Rio de Janeiro (RDJ) in healthy adults.

J Immune Based Ther Vaccines 2006 Sep 6;4. Epub 2006 Sep 6.

Centro de Pesquisas Arlindo de Assis, Fundação Ataulpho de Paiva, Avenida Almirante Barroso, 54, Andar, Rio de Janeiro, Brazil.

Background: Oral administration of BCG was the route initially used by Calmette and Guérin, but was replaced by intradermal administration in virtually all countries after the Lubeck accident. However, Brazil continued to administer oral BCG Moreau RDJ, which was maintained until the mid-1970s when it was substituted by the intradermal route. Although BCG vaccination has been used in humans since 1921, little is known of the induced immune response. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-8518-4-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1569376PMC
September 2006
12 Reads

Levamizole enhances immune responsiveness to intra-dermal and intra-muscular hepatitis B vaccination in chronic hemodialysis patients.

J Immune Based Ther Vaccines 2006 May 30;4. Epub 2006 May 30.

Division of nephrology, Modarres hospital, Shahid beheshti university of medical sciences, Tehran, Iran.

Background: Hemodialysis patient are at high risk for hepatitis B virus (HBV) infection. Although preventive vaccination is done routinely, the response to vaccination is low in this patient population. The aim of this study was to evaluate the effect of Levamizol, an enhancer of the immune responsiveness, on different routes of vaccination, i. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-8518-4-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1540413PMC
May 2006
5 Reads

A novel method to identify and characterise peptide mimotopes of heat shock protein 70-associated antigens.

J Immune Based Ther Vaccines 2006 Apr 8;4. Epub 2006 Apr 8.

Moyne Institute for Preventive Medicine, Department of Microbiology, University of Dublin, Trinity College, Dublin 2, Ireland.

The heat shock protein, Hsp70, has been shown to play an important role in tumour immunity. Vaccination with Hsp70-peptide complexes (Hsp70-PCs), isolated from autologous tumour cells, can induce protective immune responses. We have developed a novel method to identify synthetic mimic peptides of Hsp70-PCs and to test their ability to activate T-cells. Read More

View Article

Download full-text PDF

Source
http://www.springerlink.com/index/9Q4PU10655707532.pdf
Web Search
http://jibtherapies.biomedcentral.com/articles/10.1186/1476-
Publisher Site
http://dx.doi.org/10.1186/1476-8518-4-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1482705PMC
April 2006
15 Reads

Cellular metabolism as a basis for immune privilege.

J Immune Based Ther Vaccines 2006 Mar 17;4. Epub 2006 Mar 17.

The Institute for Bioenergetics, University of Colorado at Colorado Springs, Colorado Springs, CO 80933-7150, USA.

We hypothesize that the energy strategy of a cell is a key factor for determining how, or if, the immune system interacts with that cell. Cells have a limited number of metabolic states, in part, depending on the type of fuels the cell consumes. Cellular fuels include glucose (carbohydrates), lipids (fats), and proteins. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-8518-4-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1456959PMC
March 2006
5 Reads

Mycobacterial immune reconstitution inflammatory syndrome in HIV-1 infection after antiretroviral therapy is associated with deregulated specific T-cell responses: beneficial effect of IL-2 and GM-CSF immunotherapy.

J Immune Based Ther Vaccines 2005 Sep 25;3. Epub 2005 Sep 25.

Department of Immunology, Imperial College London, Chelsea and Westminster Hospital, London, UK.

Background: With the advent of antiretroviral therapy (ART) cases of immune reconstitution inflammatory syndrome (IRIS) have increasingly been reported. IRIS usually occurs in individuals with a rapidly rising CD4 T-cell count or percentage upon initiation of ART, who develop a deregulated immune response to infection with or without reactivation of opportunistic organisms. Here, we evaluated rises in absolute CD4 T-cells, and specific CD4 T-cell responses in 4 HIV-1+ individuals presenting with mycobacterial associated IRIS who received in conjunction with ART, IL-2 plus GM-CSF immunotherapy. Read More

View Article

Download full-text PDF

Source
http://jibtherapies.biomedcentral.com/articles/10.1186/1476-
Publisher Site
http://dx.doi.org/10.1186/1476-8518-3-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1262752PMC
September 2005
6 Reads

Psoriatic arthritis: pathogenesis and novel immunomodulatory approaches to treatment.

J Immune Based Ther Vaccines 2005 Sep 2;3. Epub 2005 Sep 2.

Center for Innovative Therapy, Division of Rheumatology, Allergy, and Immunology, The University of California, San Diego, La Jolla, CA 92093-0943, USA.

Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy characterized by the association of arthritis and psoriasis. PsA runs a variable course, from mild synovitis to severe, progressive, erosive arthropathy. The pathogenesis of PsA involves alteration in the components of the immune response, although the exact cause of PsA is unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-8518-3-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1208938PMC
September 2005
7 Reads